Chargement en cours...
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate...
Enregistré dans:
| Publié dans: | Adv Ther |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467473/ https://ncbi.nlm.nih.gov/pubmed/32112280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01260-x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|